This is a working overview of metabolic modulator, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-03. Anything still debated is marked as such rather than presented as settled.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
== Early life == Rosanna Jeanne Reardon was born on June 8, 1985, in Seattle, Washington, where she was raised alongside her younger sister Molly Lu. She is of Italian, Croatian, German, and Irish ancestry. She was baptized Catholic. Throughout her childhood, she was known by friends and family as a "nerdy", "awkward" kid, and she struggled with dyslexia and ADHD in school. She originally wanted to become an actress, and after attending West Seattle High School and Pacific Lutheran University, she moved to Los Angeles to pursue acting. Prior to her YouTube career, Pansino worked as a teacher in China and as a Methodist church secretary. Pansino's interest in cooking was inspired by her father and grandmother, and she stated in 2014 that "...baking has always been a hobby of mine. I have always loved being creative with my food and making themed sweets for my friends."
Though once thought of as scavengers, Neanderthals are now considered apex predators. They appear to have eaten predominantly what was abundant within their immediate surroundings, consequently consuming across their range a wide array of meats and plants, the relative proportion of which varied substantially geographically. Cro-Magnons, in contrast, seem to have maintained a more diverse diet even in settings where certain foods would have been harder to procure; for example, Neanderthals living in forests ate about the same proportion of foodplants as Cro-Magnons, but Neanderthals on open steppe (where foodplants are harder to find) ate far less foodplants. In many European sites, prey items include red deer, reindeer, horse, aurochs, ibex, and steppe bison. Neanderthals in Southwest Asia more commonly hunted mountain gazelle, Persian fallow deer, wild goat, and camels. They may have less frequently taken down larger Pleistocene megafauna whenever locally abundant, such as woolly mammoth and woolly rhinoceros. At the 125,000 year old Neumark-Nord site, Germany, there is evidence of regular hunting of straight-tusked elephants maybe every 5 to 6 years. Some waterside communities ate fish and shellfish—and at Vanguard Cave, Gibraltar, dolphin and Mediterranean monk seal. Neanderthals also hunted small game, and some caves show evidence of regular rabbit and tortoise consumption. At Gibraltar sites, there are butchered remains of 143 different bird species, many ground-dwelling such as the common quail, corn crake, woodlark, and crested lark.
However, comparisons with supervolcanoes are more misleading than helpful due to the different aerosols released, the likely air burst fuzing height of nuclear weapons and the globally scattered location of these potential nuclear detonations all being in contrast to the singular and subterranean nature of a supervolcanic eruption. Moreover, assuming the entire world stockpile of weapons were grouped together, it would be difficult, due to the nuclear fratricide effect, to ensure the individual weapons would go off all at once. Nonetheless, many people believe that a full-scale nuclear war would result, through the nuclear winter effect, in the human extinction, though not all analysts agree on the assumptions that underpin these nuclear winter models. On 26 September 1983, a Soviet early warning station under the command of Stanislav Petrov falsely detected 5 inbound intercontinental ballistic missiles from the US. Petrov correctly assessed the situation as a false alarm, and hence did not report his finding to his superiors. It is quite possible that his actions prevented "World War III", as the Soviet policy at that time was immediate nuclear response upon discovering inbound ballistic missiles. The world came unusually close to nuclear war in November 1983 when the Soviet Union thought that the NATO military exercise Able Archer 83 was a ruse or "cover-up" to begin a nuclear first strike. The Soviets responded by raising readiness and preparing their nuclear arsenal for immediate use. Soviet fears of an attack ceased once the exercise concluded without incident.
=== Targeted protein degradation === Based on the finding that thalidomide and related analogues bind CRBN, heterobifunctional molecules were designed linking thalidomide to ligands for other proteins of interest. These molecules, termed proteolysis targeting chimeras (PROTACs) or protein degraders, recruit CRBN to a protein of interest, leading to its ubiquitination and subsequent degradation. This technology is being explored in clinical trials by a number of biotechnology companies such as Arvinas, C4 Therapeutics, and Kymera Therapeutics.
Sources: en.wikipedia.org
Texts on Wikisource: Chisholm, Hugh, ed. (1911). "Amines" . Encyclopædia Britannica (11th ed.). Cambridge University Press. Synthesis of amines Factsheet, amines in food Archived 19 February 2018 at the Wayback Machine
At the third AU summit, held in Tripoli, Libya, in July 2005, Gaddafi called for greater integration, advocating a single AU passport, a common defence system, and a single currency, using the slogan: "The United States of Africa is the hope." His proposal for a Union of African States, a project originally conceived by Ghana's Kwame Nkrumah in the 1960s, was rejected at the 2001 Assembly of Heads of States and Government (AHSG) summit in Lusaka by African leaders who thought it "unrealistic" and "utopian". In June 2005, Libya joined the Common Market for Eastern and Southern Africa (COMESA). In March 2008 in Uganda, Gaddafi gave a speech once again urging Africa to reject foreign aid. In August 2008, Gaddafi was proclaimed "King of Kings" by a committee of traditional African leaders; they crowned him in February 2009, in a ceremony held in Addis Ababa, Ethiopia. That same month, Gaddafi was elected as the chairperson of the African Union, a position he retained for one year. In October 2010, Gaddafi apologized to African leaders for the historical enslavement of Africans by the Arab slave trade.
However, after identification of the corresponding active gene clusters, these genes can be cloned into yeast and expressed as well to produce the product of interest in a more cost and time effective way. This method can also be used to discover new drugs. In this experiment, previously unstudied fungal genetic sequences can be characterized and expressed, which allows the production of new natural products. However, with mutagenesis of genes towards a more biologically relevant compound, this can then be expressed to yield a new genetically modified product. Another important use of heterologous expression is to screen different drugs in a host system rather than a more expensive or difficult to sustain native system. An example of this would be using Mycobacterium marinum as an alternative host system compared to directly using Mycobacterium tuberculosis. M. tuberculosis requires high biosafety level facilities for drug screening and has a slow growth rate which makes the process expensive and time-consuming. Therefore, researchers tested a closely related and less hazardous M. marinum, which heterologous expression of two drug activators, became an accurate model to test tuberculosis drugs in. An example examining a more focused drug target is the heterologous expression of ion channel proteins to test different cardiac ion channel drugs that alter their function to address heart disease. Similarly, drug screening can occur with heterologous expression of cloned receptors.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.